Enliven's ELVN-001 Shows Strong Phase 1b CML Data, Securing Cash Runway into 2029
ELVN has more than doubled off its 52-week low of $13.3.
Summary
Enliven Therapeutics reported positive initial Phase 1b data for its lead candidate, ELVN-001, in patients with chronic myeloid leukemia (CML) who were heavily pretreated. The data showed promising Major Molecular Response (MMR) rates, with 69% in the 60/120 mg QD cohort, supporting the company's belief in ELVN-001's "best-in-class" potential. This significant clinical progress is coupled with a strong financial position, as the company reported $463 million in cash, cash equivalents, and marketable securities, extending its cash runway into the first half of 2029. This update de-risks the company's lead asset and provides substantial financial stability, paving the way for the planned initiation of the pivotal Phase 3 ENABLE-2 trial in the second half of 2026. Traders will be watching for further Phase 1 data presentations and regulatory alignment with the FDA.
At the time of this announcement, ELVN was trading at $28.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $13.30 to $30.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.